Effects of ACEI on Bone Turnover

Completed

• Conditions: Bone Turnover Status in Hypertensive Patients

• Registration Number: NCT02377440
• Lead Sponsor: The University of Texas Health Science Center, Houston

Brief Summary

The investigators hypothesize that older persons (≥45 years) treated with ACEI for HTN control will have: i) improved status of bone turnover (decreased P1NP and CTX), and ii) decreased levels of RANKL and RANKL/OPG, compared to those not treated with ACEI and not using RAS-related medications

Detailed Description

Not available

Study Timeline

• Study Start: 2013-10
• Study First Submitted: 2014-03-19
• Study First Submitted QC: 2015-02-25
• Study First Posted: 2015-03-03
• Status Verified: 2015-12
• Primary Completion: 2015-12
• Study Completion: 2015-12
• Last Update Submitted: 2015-12-03
• Last Update Posted: 2015-12-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

• at least 45 years of age
• a diagnosis of (either new or uncontrolled) HTN who will need a new medication for HTN control
• able to consent (no medial issues impairing judgment for consenting based on clinical providers' judgment).

Exclusion Criteria

• younger than 45 years of age
• a diagnosis of metabolic bone disease
• a diagnosis of osteoporosis or use of medication to treat osteoporosis
• a diagnosis of diabetes mellitus, or renal insufficiency, or cancer
• history of allergy to ACEI or ARB, 6) history of use of ACEI or ARB.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in serum CTX levels in pg/mL	baseline, 3 months

Trial Locations

Locations (2)

Nahid Rianon, MD; 🇺🇸 Houston, Texas, United States

University of Texas Medical School at Houston; 🇺🇸 Houston, Texas, United States